Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression | Zendy

Leonidas Apostolidis | Zendy; Jan Pfeiffenberger | Zendy; Daniel Gotthardt | Zendy; Boris Radeleff | Zendy; Arianeb Mehrabi | Zendy; Peter Schemmer | Zendy; Dirk Jäger | Zendy; Peter Schirmacher | Zendy; Wolfgang Stremmel | Zendy; Henning SchulzeBergkamen | Zendy; Christoph Springfeld | Zendy; Karl Heinz Weiss | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression

Author(s) -

Leonidas Apostolidis,

Jan Pfeiffenberger,

Daniel Gotthardt,

Boris Radeleff,

Arianeb Mehrabi,

Peter Schemmer,

Dirk Jäger,

Peter Schirmacher,

Wolfgang Stremmel,

Henning SchulzeBergkamen,

Christoph Springfeld,

Karl Heinz Weiss

Publication year - 2018

Publication title -

gastrointestinal tumors

Language(s) - English

Resource type - Journals

eISSN - 2296-3766

pISSN - 2296-3774

DOI - 10.1159/000487635

Subject(s) - sorafenib , medicine , hepatocellular carcinoma , tumor progression , retrospective cohort study , overall survival , oncology , gastroenterology , surgery , cancer

Sorafenib leads to improved survival in advanced hepatocellular carcinoma (HCC) patients. Continuation of sorafenib beyond progression has been a possible treatment strategy when further approved therapeutic agents are lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research